Bennicas & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Bennicas & Associates’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$909K	Hold	1,260	–	–	0.53%	58
2022 Q3	$868K	Sell	1,260 -100	-7%	-$62.9K	0.55%	56
2022 Q2	$804K	Sell	1,360 -50	-4%	-$32.5K	0.47%	60
2022 Q1	$985K	Sell	1,410 -75	-5%	-$47.4K	0.49%	60
2021 Q4	$938K	Hold	1,485	–	–	0.49%	64
2021 Q3	$899K	Hold	1,485	–	–	0.51%	64
2021 Q2	$829K	Hold	1,485	–	–	0.46%	66
2021 Q1	$703K	Hold	1,485	–	–	0.4%	66
2020 Q4	$717K	Hold	1,485	–	–	0.42%	64
2020 Q3	$831K	Hold	1,485	–	–	0.52%	59
2020 Q2	$926K	Hold	1,485	–	–	0.7%	46
2020 Q1	$725K	Sell	1,485 -150	-9%	-$61.9K	0.64%	44
2019 Q4	$614K	Sell	1,635 -150	-8%	-$50.5K	0.44%	59
2019 Q3	$495K	Hold	1,785	–	–	0.38%	58
2019 Q2	$559K	Hold	1,785	–	–	0.47%	57
2019 Q1	$733K	Sell	1,785 -20	-1%	-$8.24K	0.64%	53
2018 Q4	$674K	Hold	1,805	–	–	0.62%	56
2018 Q3	$729K	Hold	1,805	–	–	0.63%	57
2018 Q2	$623K	Hold	1,805	–	–	0.55%	62
2018 Q1	$622K	Sell	1,805 -95	-5%	-$33K	0.56%	60
2017 Q4	$714K	Hold	1,900	–	–	0.62%	56
2017 Q3	$850K	Hold	1,900	–	–	0.72%	52
2017 Q2	$933K	Hold	1,900	–	–	0.84%	45
2017 Q1	$736K	Sell	1,900 -50	-3%	-$18.5K	0.66%	53
2016 Q4	$716K	Buy	+1,950	New	+$742K	0.65%	54

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bennicas & Associates's REGN Position: Q4 2022 in Review

Bennicas & Associates held its Regeneron Pharmaceuticals (REGN) position steady in Q4 2022 at 1,260 shares worth $909K. The position accounts for 0.53% of the portfolio, ranked #58.

Bennicas & Associates first reported a position in REGN in Q4 2016 and has held it in 25 quarters since. The position peaked at $985K in Q1 2022. 1,159 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

Bennicas & Associates held 1,260 shares of Regeneron Pharmaceuticals worth $909K as of Q4 2022.
Bennicas & Associates left its Regeneron Pharmaceuticals share count unchanged in Q4 2022.
Regeneron Pharmaceuticals made up 0.53% of Bennicas & Associates's portfolio in Q4 2022, its #58 holding.
Bennicas & Associates first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 25 quarters since.
Bennicas & Associates's Regeneron Pharmaceuticals position peaked at $985K in Q1 2022.
1,159 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Bennicas & Associates's 13F filing for Q4 2022, filed 12 Jan 2023.